Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

PDF] Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer

PDF] Immunotherapy in oncogene addicted non-small cell lung cancer

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing

Frontiers Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

POR KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges

PDF) Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene

TERT Mutations in Non–Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Implications - Liu Yang, Meng Wang, Na Li, Lu-Da Yan, Wen Zhou, Zhi-Qiong Yu, Xiao-Chun Peng, Jun Cai, Yong-Hua Yang, 2023

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer

Increasing Therapy Options in Solid Tumours: A Consideration of Testing Methodologies in Non-small Cell Lung Cancer and Breast Cancer - European Medical Journal